Eisana, Cortex Design Partner to Combat Painful Chemo Side Effects

Cancer treatment side effects treatment firm Eisana Corporation and design engineering firm Cortex Design have inked an agreement to develop Eisana’s first product, a tech-enabled device to prevent chemotherapy-induced peripheral neuropathy (CIPN).
 
500,000 cancer patients a year in the U.S. can suffer from CIPN. The condition is sometimes permanent. Studies show cooling the hands and feet can prevent nerve damage causing CIPN by constricting blood vessels.
 
There are currently no U.S. Food and Drug Administration (FDA)-cleared devices on the market to prevent CIPN.
 
“I couldn’t be more thrilled with our newly formed relationship with Cortex,” Carole Spangler Vaughn, Ph.D., MBA, CEO and founder of Eisana told the press. “They have the intellectual bandwidth, depth of experience, as well as passion for the project, to take it to the finish line.”
 
Cortex also committed to being the lead investor in Eisana’s pre-seed round, targeting a $600,000 raise.
 
“When we heard about the mission of Eisana, we were really inspired. We want to do everything we can to help,” said James Chalmers, Partner and Chief Strategist at Cortex. “Nothing would make us happier than having these devices give cancer patients a better life after treatment.”
 
“Cortex‘s position as a lead investor truly demonstrates a real commitment to getting this product to market and a confirmation of our united mission,” said Vaughn.
 
“Having gone through cancer treatment myself, I know how important these products are,” Vaughn continued. “Having cancer is hard enough without additional side effects. Providing these devices will allow us to completely redefine how cancer patients experience treatment by making chemotherapy far less devastating.”